$7.2 Billion Blockbuster Deal Puts Medical Cannabis Sector In The SpotlightPosted by On


The latest deal creating a buzz in the cannabis industry is the US$7.2-billion takeover of GW Pharma (NASDAQ:) by a little-known, Ireland-based company—Jazz Pharmaceuticals (NASDAQ:).

The acquisition announced last week is the biggest takeover in the marijuana industry, and could have wide implications for the growing cannabinoid-based medication sector.

JAZZ Daily

GW Pharma is the UK-based company that was the first firm to market a drug that used purified CBD—the non-psychoactive component of cannabis—that is now used to treat children who suffer from severe epilepsy. The drug, Epidiolex, was approved by the U.S. Food and Drug Administration in 2018. The company is also in testing trials for other cannabis-based treatments for multiple sclerosis, autism and schizophrenia.

Jazz Pharmaceuticals markets a number of cancer drugs as well as a leading treatment for narcolepsy, a chronic sleep disorder that prompt severe bouts of daytime drowsiness.

Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals said:

“Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business. We are excited to add GW’s industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities.”

The deal points to a…

Original Author Link click here to read complete story..

The latest deal creating a buzz in the cannabis industry is the US$7.2-billion takeover of GW Pharma (NASDAQ:) by a little-known, Ireland-based company—Jazz Pharmaceuticals (NASDAQ:).

The acquisition announced last week is the biggest takeover in the marijuana industry, and could have wide implications for the growing cannabinoid-based medication sector.

JAZZ Daily

GW Pharma is the UK-based company that was the first firm to market a drug that used purified CBD—the non-psychoactive component of cannabis—that is now used to treat children who suffer from severe epilepsy. The drug, Epidiolex, was approved by the U.S. Food and Drug Administration in 2018. The company is also in testing trials for other cannabis-based treatments for multiple sclerosis, autism and schizophrenia.

Jazz Pharmaceuticals markets a number of cancer drugs as well as a leading treatment for narcolepsy, a chronic sleep disorder that prompt severe bouts of daytime drowsiness.

Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals said:

“Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business. We are excited to add GW’s industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities.”

The deal points to a…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.